Home›Estrogens

Estrogens

94 interactions on record

Estrogens has 94 known drug interactions based on U.S. FDA drug labeling data. Of these, 5 are contraindicated combinations that should be avoided entirely. 4 are classified as major interactions requiring close medical supervision. Notable interactions include combinations with Anastrozole, Eletriptan Hydrobromide, Ospemifene. Patients taking Estrogens should inform their healthcare provider of all current medications — including over-the-counter drugs and supplements — to avoid potentially harmful combinations. Data sourced from OpenFDA and the NIH National Library of Medicine.

Total: 94
Contraindicated: 5
Major: 4
Moderate: 84
Minor: 1

Contraindicated (5)

Estrogens + Anastrozole— Estrogen-containing therapies should not be used with anastrozole as they may diminish its pharmacological action.
Estrogens + Eletriptan Hydrobromide— Concomitant use of other 5-HT1 agonists within 24 hours of eletriptan is contraindicated due to additive effects.
Estrogens + Ospemifene— Do not use estrogens concomitantly with ospemifene. Safety of concomitant use has not been studied.
Estrogens + Raloxifene Hydrochloride— Safety of concomitant use has not been established and use is not recommended.
Estrogens + Rizatriptan Benzoate— Other 5-HT1 agonists have additive vasospastic effects. Coadministration within 24 hours of rizatriptan benzoate is cont…

Major (4)

Estrogens + Insulin Glargine— May decrease blood glucose lowering effect of LANTUS. Dosage increases and increased glucose monitoring may be required.
Estrogens + Lenalidomide— Concomitant use with lenalidomide may increase the risk of thrombosis. Use with caution after benefit-risk assessment.
Estrogens + Raloxifene— Safety of concomitant use has not been established and use is not recommended.
Estrogens + Ticagrelor— Opioids delay and reduce absorption of ticagrelor and its active metabolite. Consider parenteral anti-platelet agent in …

Moderate (84)

Estrogens + Acarbose— Estrogens produce hyperglycemia and may lead to loss of blood glucose control in patients receiving Acarbose. Close obse…
Estrogens + Alogliptin And Metformin Hydrochloride— May produce hyperglycemia and lead to loss of glycemic control.
Estrogens + Betamethasone Sodium Phosphate, Betamethasone Acetate, Lidocaine, Iodixanol, Povidine Iodine— May decrease hepatic metabolism of certain corticosteroids, thereby increasing their effect.
Estrogens + Calcium Chloride— Increases risk of hypercalcemia when used concomitantly. Increase frequency of calcium concentration monitoring.
Estrogens + Calcium Chloride Dihydrate— Increases risk of hypercalcemia. Increase frequency of calcium concentration monitoring.
Estrogens + Calcium Gluconate— Concurrent administration may cause hypercalcemia. Monitor plasma calcium concentrations.
Estrogens + Chenodiol— Increases biliary cholesterol secretion and may counteract the effectiveness of chenodiol.
Estrogens + Cholestyramine Light— Cholestyramine may delay or reduce the absorption of estrogens.
Estrogens + Cholestyramine Powder For Suspension— Cholestyramine may delay or reduce the absorption of estrogens.
Estrogens + Choleystyramine Light— Cholestyramine may delay or reduce absorption of estrogens.
Estrogens + Cosyntropin— May elevate plasma total cortisol levels and affect test accuracy. Stop estrogen-containing drugs 4-6 weeks before COSYN…
Estrogens + Dantrolene Sodium— Caution advised with concomitant use. Hepatotoxicity has occurred more often in women over 35 years receiving concurrent…
Estrogens + Dapagliflozin And Metformin Hydrochloride— Produce hyperglycemia and may lead to loss of glycemic control when used with XIGDUO XR.
Estrogens + Depo-Medrol, Lidocaine, Isopropyl Alcohol— Estrogens may decrease hepatic metabolism of certain corticosteroids, increasing their effect.
Estrogens + Dexamethasone— Estrogens may decrease hepatic metabolism of dexamethasone, thereby increasing its effect.
Estrogens + Dexamethasone 1.5 Mg— Estrogens may decrease hepatic metabolism of dexamethasone, thereby increasing its effect.
Estrogens + Dexamethasone Intensol— Estrogens may decrease hepatic metabolism of dexamethasone, thereby increasing its effect.
Estrogens + Empagliflozin, Metformin Hydrochloride— May produce hyperglycemia and lead to loss of glycemic control; monitor closely.
Estrogens + Ertugliflozin And Metformin Hydrochloride— May produce hyperglycemia and lead to loss of glycemic control; close monitoring recommended.
Estrogens + Fludrocortisone Acetate— Increased levels of corticosteroid-binding globulin increasing bound inactive fraction. May require reduction in cortico…
Estrogens + Fosphenytoin Sodium— May increase phenytoin serum levels; monitoring of phenytoin levels recommended.
Estrogens + Glibenclamide— Estrogens may produce hyperglycemia and lead to loss of control of glyburide. Patients should be closely observed for lo…
Estrogens + Glimepiride— May reduce glucose-lowering effect of glimepiride, leading to worsening glycemic control.
Estrogens + Glipizide— Estrogens may produce hyperglycemia and lead to loss of glycemic control. Patient should be observed closely for loss of…
Estrogens + Glipizide And Metformin Hydrochloride— Estrogens may produce hyperglycemia and lead to loss of blood glucose control. Patient should be closely observed for lo…
Estrogens + Glyburide And Metformin Hydrochloride— Estrogens tend to produce hyperglycemia and may lead to loss of blood glucose control. Close observation required.
Estrogens + Griseofulvin— Griseofulvin may enhance hepatic metabolism of estrogens, reducing effectiveness and causing menstrual irregularities. A…
Estrogens + Hemin— CYP inducing drugs increase activity of ALAS leading to induction of ALAS1 through feedback mechanism, counteracting PAN…
Estrogens + Hyaluronidase— Large doses of estrogens may require larger amounts of hyaluronidase for equivalent dispersing effect; these drugs rende…
Estrogens + Hyaluronidase, Ovine— Large doses may require larger amounts of hyaluronidase for equivalent dispersing effect; tissues become partly resistan…
Estrogens + Hydrocortisone— May increase serum cortisol-binding globulin, reducing hydrocortisone efficacy; may require dose increase.
Estrogens + Hydrocortisone Acetate— Estrogens may decrease hepatic metabolism of corticosteroids, increasing their effect.
Estrogens + Hydrocortisone Sodium Succinate— Estrogens may decrease hepatic metabolism of certain corticosteroids, thereby increasing their effect.
Estrogens + Insulin Aspart Injection— May decrease blood glucose lowering effect. Dose adjustment and increased glucose monitoring may be required.
Estrogens + Insulin Aspart-Szjj— May decrease blood glucose lowering effect. Dose adjustment and increased glucose monitoring may be required.
Estrogens + Insulin Degludec— May decrease blood glucose lowering effect. Dosage increases and increased glucose monitoring may be required.
Estrogens + Insulin Degludec And Liraglutide— May decrease blood glucose-lowering effect; dosage increases and increased glucose monitoring may be required.
Estrogens + Insulin Detemir— May decrease blood glucose lowering effect of insulin detemir. Dosage increases and increased glucose monitoring may be …
Estrogens + Insulin Glargine And Lixisenatide— May decrease the blood glucose lowering effect. Dose increases and increased glucose monitoring may be required.
Estrogens + Insulin Glargine-Aglr— May decrease blood glucose lowering effect. Dosage increases and increased glucose monitoring may be required.
Estrogens + Insulin Glargine-Yfgn— May decrease blood glucose lowering effect. Dosage increases and increased glucose monitoring may be required.
Estrogens + Insulin Glulisine— May decrease blood glucose lowering effect. Dose adjustment and increased glucose monitoring may be required.
Estrogens + Insulin Human— May decrease blood glucose lowering effect; dose adjustment and increased glucose monitoring may be required.
Estrogens + Insulin Lispro— May decrease the blood glucose lowering effect. Dose adjustment and increased frequency of glucose monitoring may be req…
Estrogens + Insulin Lispro-Aabc— May decrease blood glucose lowering effect. Dose increases and increased glucose monitoring may be required.
Estrogens + Ipratropium Bromide And Albuterol Sulfate— Mutual inhibition of effects; β-blockers should be used cautiously in hyperreactive airways patients, with preference fo…
Estrogens + Kenalog— Estrogens may decrease hepatic metabolism of corticosteroids, thereby increasing their effect.
Estrogens + Levothyroxine And Liothyronine— Estrogens increase serum thyroxine-binding globulin, potentially decreasing free levothyroxine. Patients without functio…
Estrogens + Levothyroxine Sodium— May increase serum thyroxine-binding globulin concentration, resulting in initial transient increase in FT4 followed by …
Estrogens + Linagliptin And Metformin Hydrochloride— Estrogens may produce hyperglycemia and lead to loss of glycemic control. Close monitoring of glycemic control is recomm…
Estrogens + Liothyronine Sodium— Oral estrogens may increase serum thyroxine-binding globulin concentration, altering T3 serum transport. Closely monitor…
Estrogens + Lonapegsomatropin-Tcgd— Oral estrogens may reduce the serum IGF-1 response to SKYTROFA. Patients receiving oral estrogen replacement may require…
Estrogens + Marcaine, Lidocaine, Kenalog, Povidone Iodine— Estrogens may decrease hepatic metabolism of corticosteroids, increasing their effect.
Estrogens + Metformin— Produce hyperglycemia and may lead to loss of glycemic control when used with metformin.
Estrogens + Metformin Er 500 Mg— May produce hyperglycemia and lead to loss of glycemic control. Monitor patient closely for loss of blood glucose contro…
Estrogens + Metformin Hydrochloride— Drugs that produce hyperglycemia and may lead to loss of glycemic control; monitor blood glucose.
Estrogens + Metformin Hydrochloride Extended-Release Tablets— May produce hyperglycemia and lead to loss of glycemic control during metformin therapy; monitor blood glucose.
Estrogens + Metformin Hydrochloride Tablet— May produce hyperglycemia and lead to loss of glycemic control when used with metformin.
Estrogens + Methylprednisolone— Estrogens may decrease hepatic metabolism of certain corticosteroids, thereby increasing their effect.
Estrogens + Methylprednisolone Acetate— Estrogens may decrease hepatic metabolism of corticosteroids, thereby increasing their effect.
Estrogens + Methylprednisolone Acetate, Lidocaine Hydrochloride, Povidine Iodine, Isopropyl Alcohol— Estrogens may decrease hepatic metabolism of certain corticosteroids, increasing their effect.
Estrogens + Methylprednisolone Sodium Succinate— Estrogens may decrease the hepatic metabolism of certain corticosteroids, thereby increasing their effect.
Estrogens + Phenytoin— May increase phenytoin serum levels; monitoring of phenytoin levels recommended.
Estrogens + Phenytoin Sodium— May increase phenytoin serum levels; monitoring of phenytoin levels recommended.
Estrogens + Prasugrel— Delay and reduce absorption of prasugrel's active metabolite due to slowed gastric emptying. Consider parenteral antipla…
Estrogens + Prasugrel Hydrochloride— Opioid agonists delay and reduce absorption of prasugrel's active metabolite, presumably due to slowed gastric emptying.…
Estrogens + Prednisolone Sodium Phosphate— Estrogens decrease hepatic metabolism of certain corticosteroids, increasing their effect.
Estrogens + Prednisone— Estrogens may decrease hepatic metabolism of corticosteroids, thereby increasing their effect.
Estrogens + Rifampin— Rifampin decreases estrogen exposure. Advise patients to change to non-hormonal birth control methods during rifampin th…
Estrogens + Ropinirole— Higher doses of estrogens reduce clearance of ropinirole; starting or stopping hormone replacement therapy may require r…
Estrogens + Sitagliptin And Metformin Hydrochloride— May produce hyperglycemia and lead to loss of glycemic control. Monitor blood glucose closely during concomitant use.
Estrogens + Somapacitan-Beco— Oral estrogens may reduce the serum IGF-1 response to SOGROYA, potentially requiring higher SOGROYA dosages.
Estrogens + Somatrogon-Ghla— Oral estrogens may reduce the serum IGF-1 response to NGENLA. Patients receiving oral estrogen replacement may require h…
Estrogens + Somatropin— Larger doses of somatropin may be required in women using oral estrogen.
Estrogens + Thalidomide— Estrogen-containing therapies may increase thromboembolism risk when used concomitantly with thalidomide.
Estrogens + Thyroid— Estrogens increase serum thyroxine-binding globulin, decreasing free levothyroxine. Patients without functioning thyroid…
Estrogens + Thyroid, Porcine— Increases serum thyroxine-binding globulin (TBg), decreasing free levothyroxine (T4) in patients without functioning thy…
Estrogens + Tizanidine— Concomitant use not recommended; hypotensive effects may be cumulative.
Estrogens + Tizanidine Hydrochloride— Concomitant use not recommended; hypotensive effects may be cumulative.
Estrogens + Triamcinolone Acetonide— Estrogens may decrease hepatic metabolism of corticosteroids, increasing their effect.
Estrogens + Triamcinolone Acetonide Extended-Release Injectable Suspension— Estrogens may decrease hepatic metabolism of certain corticosteroids, thereby increasing their effect.
Estrogens + Ursodiol— Increase hepatic cholesterol secretion and may counteract the effectiveness of ursodiol.
Estrogens + Ursosiol— Increase hepatic cholesterol secretion and encourage cholesterol gallstone formation, potentially counteracting ursodiol…
Estrogens + Usodiol— Increase hepatic cholesterol secretion and encourage cholesterol gallstone formation, potentially counteracting ursodiol…

Minor (1)

Estrogens + Risedronate Sodium— Risedronate sodium may be used concomitantly with hormone replacement therapy if considered appropriate; study showed no…

Estrogens + Anastrozole⛔Contraindicated

Estrogen-containing therapies should not be used with anastrozole as they may diminish its pharmacological action.

Estrogens + Eletriptan Hydrobromide⛔Contraindicated

Concomitant use of other 5-HT1 agonists within 24 hours of eletriptan is contraindicated due to additive effects.

Estrogens + Ospemifene⛔Contraindicated

Do not use estrogens concomitantly with ospemifene. Safety of concomitant use has not been studied.

Estrogens + Raloxifene Hydrochloride⛔Contraindicated

Safety of concomitant use has not been established and use is not recommended.

Estrogens + Rizatriptan Benzoate⛔Contraindicated

Other 5-HT1 agonists have additive vasospastic effects. Coadministration within 24 hours of rizatriptan benzoate is contraindicated.

Estrogens + Insulin Glargine⚠️Major

May decrease blood glucose lowering effect of LANTUS. Dosage increases and increased glucose monitoring may be required.

Estrogens + Lenalidomide⚠️Major

Concomitant use with lenalidomide may increase the risk of thrombosis. Use with caution after benefit-risk assessment.

Estrogens + Raloxifene⚠️Major

Safety of concomitant use has not been established and use is not recommended.

Estrogens + Ticagrelor⚠️Major

Opioids delay and reduce absorption of ticagrelor and its active metabolite. Consider parenteral anti-platelet agent in acute coronary syndrome patients.

Estrogens + Acarbose🟡Moderate

Estrogens produce hyperglycemia and may lead to loss of blood glucose control in patients receiving Acarbose. Close observation for loss of glucose control is recommended.

Estrogens + Alogliptin And Metformin Hydrochloride🟡Moderate

May produce hyperglycemia and lead to loss of glycemic control.

Estrogens + Betamethasone Sodium Phosphate, Betamethasone Acetate, Lidocaine, Iodixanol, Povidine Iodine🟡Moderate

May decrease hepatic metabolism of certain corticosteroids, thereby increasing their effect.

Estrogens + Calcium Chloride🟡Moderate

Increases risk of hypercalcemia when used concomitantly. Increase frequency of calcium concentration monitoring.

Estrogens + Calcium Chloride Dihydrate🟡Moderate

Increases risk of hypercalcemia. Increase frequency of calcium concentration monitoring.

Estrogens + Calcium Gluconate🟡Moderate

Concurrent administration may cause hypercalcemia. Monitor plasma calcium concentrations.

Estrogens + Chenodiol🟡Moderate

Increases biliary cholesterol secretion and may counteract the effectiveness of chenodiol.

Estrogens + Cholestyramine Light🟡Moderate

Cholestyramine may delay or reduce the absorption of estrogens.

Estrogens + Cholestyramine Powder For Suspension🟡Moderate

Cholestyramine may delay or reduce the absorption of estrogens.

Estrogens + Choleystyramine Light🟡Moderate

Cholestyramine may delay or reduce absorption of estrogens.

Estrogens + Cosyntropin🟡Moderate

May elevate plasma total cortisol levels and affect test accuracy. Stop estrogen-containing drugs 4-6 weeks before COSYNTROPIN testing to allow cortisol binding globulin normalization.

Estrogens + Dantrolene Sodium🟡Moderate

Caution advised with concomitant use. Hepatotoxicity has occurred more often in women over 35 years receiving concurrent estrogen therapy.

Estrogens + Dapagliflozin And Metformin Hydrochloride🟡Moderate

Produce hyperglycemia and may lead to loss of glycemic control when used with XIGDUO XR.

Estrogens + Depo-Medrol, Lidocaine, Isopropyl Alcohol🟡Moderate

Estrogens may decrease hepatic metabolism of certain corticosteroids, increasing their effect.

Estrogens + Dexamethasone🟡Moderate

Estrogens may decrease hepatic metabolism of dexamethasone, thereby increasing its effect.

Estrogens + Dexamethasone 1.5 Mg🟡Moderate

Estrogens may decrease hepatic metabolism of dexamethasone, thereby increasing its effect.

Estrogens + Dexamethasone Intensol🟡Moderate

Estrogens may decrease hepatic metabolism of dexamethasone, thereby increasing its effect.

Estrogens + Empagliflozin, Metformin Hydrochloride🟡Moderate

May produce hyperglycemia and lead to loss of glycemic control; monitor closely.

Estrogens + Ertugliflozin And Metformin Hydrochloride🟡Moderate

May produce hyperglycemia and lead to loss of glycemic control; close monitoring recommended.

Estrogens + Fludrocortisone Acetate🟡Moderate

Increased levels of corticosteroid-binding globulin increasing bound inactive fraction. May require reduction in corticosteroid dosage when initiated and increased amounts when terminated.

Estrogens + Fosphenytoin Sodium🟡Moderate

May increase phenytoin serum levels; monitoring of phenytoin levels recommended.

Estrogens + Glibenclamide🟡Moderate

Estrogens may produce hyperglycemia and lead to loss of control of glyburide. Patients should be closely observed for loss of control.

Estrogens + Glimepiride🟡Moderate

May reduce glucose-lowering effect of glimepiride, leading to worsening glycemic control.

Estrogens + Glipizide🟡Moderate

Estrogens may produce hyperglycemia and lead to loss of glycemic control. Patient should be observed closely for loss of control when initiated or withdrawn.

Estrogens + Glipizide And Metformin Hydrochloride🟡Moderate

Estrogens may produce hyperglycemia and lead to loss of blood glucose control. Patient should be closely observed for loss of blood glucose control.

Estrogens + Glyburide And Metformin Hydrochloride🟡Moderate

Estrogens tend to produce hyperglycemia and may lead to loss of blood glucose control. Close observation required.

Estrogens + Griseofulvin🟡Moderate

Griseofulvin may enhance hepatic metabolism of estrogens, reducing effectiveness and causing menstrual irregularities. Alternate birth control may be indicated.

Estrogens + Hemin🟡Moderate

CYP inducing drugs increase activity of ALAS leading to induction of ALAS1 through feedback mechanism, counteracting PANHEMATIN therapy.

Estrogens + Hyaluronidase🟡Moderate

Large doses of estrogens may require larger amounts of hyaluronidase for equivalent dispersing effect; these drugs render tissues partly resistant to hyaluronidase action.

Estrogens + Hyaluronidase, Ovine🟡Moderate

Large doses may require larger amounts of hyaluronidase for equivalent dispersing effect; tissues become partly resistant to hyaluronidase action.

Estrogens + Hydrocortisone🟡Moderate

May increase serum cortisol-binding globulin, reducing hydrocortisone efficacy; may require dose increase.

Estrogens + Hydrocortisone Acetate🟡Moderate

Estrogens may decrease hepatic metabolism of corticosteroids, increasing their effect.

Estrogens + Hydrocortisone Sodium Succinate🟡Moderate

Estrogens may decrease hepatic metabolism of certain corticosteroids, thereby increasing their effect.

Estrogens + Insulin Aspart Injection🟡Moderate

May decrease blood glucose lowering effect. Dose adjustment and increased glucose monitoring may be required.

Estrogens + Insulin Aspart-Szjj🟡Moderate

May decrease blood glucose lowering effect. Dose adjustment and increased glucose monitoring may be required.

Estrogens + Insulin Degludec🟡Moderate

May decrease blood glucose lowering effect. Dosage increases and increased glucose monitoring may be required.

Estrogens + Insulin Degludec And Liraglutide🟡Moderate

May decrease blood glucose-lowering effect; dosage increases and increased glucose monitoring may be required.

Estrogens + Insulin Detemir🟡Moderate

May decrease blood glucose lowering effect of insulin detemir. Dosage increases and increased glucose monitoring may be required.

Estrogens + Insulin Glargine And Lixisenatide🟡Moderate

May decrease the blood glucose lowering effect. Dose increases and increased glucose monitoring may be required.

Estrogens + Insulin Glargine-Aglr🟡Moderate

May decrease blood glucose lowering effect. Dosage increases and increased glucose monitoring may be required.

Estrogens + Insulin Glargine-Yfgn🟡Moderate

May decrease blood glucose lowering effect. Dosage increases and increased glucose monitoring may be required.

Estrogens + Insulin Glulisine🟡Moderate

May decrease blood glucose lowering effect. Dose adjustment and increased glucose monitoring may be required.

Estrogens + Insulin Human🟡Moderate

May decrease blood glucose lowering effect; dose adjustment and increased glucose monitoring may be required.

Estrogens + Insulin Lispro🟡Moderate

May decrease the blood glucose lowering effect. Dose adjustment and increased frequency of glucose monitoring may be required.

Estrogens + Insulin Lispro-Aabc🟡Moderate

May decrease blood glucose lowering effect. Dose increases and increased glucose monitoring may be required.

Estrogens + Ipratropium Bromide And Albuterol Sulfate🟡Moderate

Mutual inhibition of effects; β-blockers should be used cautiously in hyperreactive airways patients, with preference for β1-selective agents.

Estrogens + Kenalog🟡Moderate

Estrogens may decrease hepatic metabolism of corticosteroids, thereby increasing their effect.

Estrogens + Levothyroxine And Liothyronine🟡Moderate

Estrogens increase serum thyroxine-binding globulin, potentially decreasing free levothyroxine. Patients without functioning thyroid gland may require increased thyroid dose.

Estrogens + Levothyroxine Sodium🟡Moderate

May increase serum thyroxine-binding globulin concentration, resulting in initial transient increase in FT4 followed by decreased serum T4.

Estrogens + Linagliptin And Metformin Hydrochloride🟡Moderate

Estrogens may produce hyperglycemia and lead to loss of glycemic control. Close monitoring of glycemic control is recommended.

Estrogens + Liothyronine Sodium🟡Moderate

Oral estrogens may increase serum thyroxine-binding globulin concentration, altering T3 serum transport. Closely monitor thyroid hormone parameters.

Estrogens + Lonapegsomatropin-Tcgd🟡Moderate

Oral estrogens may reduce the serum IGF-1 response to SKYTROFA. Patients receiving oral estrogen replacement may require higher SKYTROFA dosages.

Estrogens + Marcaine, Lidocaine, Kenalog, Povidone Iodine🟡Moderate

Estrogens may decrease hepatic metabolism of corticosteroids, increasing their effect.

Estrogens + Metformin🟡Moderate

Produce hyperglycemia and may lead to loss of glycemic control when used with metformin.

Estrogens + Metformin Er 500 Mg🟡Moderate

May produce hyperglycemia and lead to loss of glycemic control. Monitor patient closely for loss of blood glucose control.

Estrogens + Metformin Hydrochloride🟡Moderate

Drugs that produce hyperglycemia and may lead to loss of glycemic control; monitor blood glucose.

Estrogens + Metformin Hydrochloride Extended-Release Tablets🟡Moderate

May produce hyperglycemia and lead to loss of glycemic control during metformin therapy; monitor blood glucose.

Estrogens + Metformin Hydrochloride Tablet🟡Moderate

May produce hyperglycemia and lead to loss of glycemic control when used with metformin.

Estrogens + Methylprednisolone🟡Moderate

Estrogens may decrease hepatic metabolism of certain corticosteroids, thereby increasing their effect.

Estrogens + Methylprednisolone Acetate🟡Moderate

Estrogens may decrease hepatic metabolism of corticosteroids, thereby increasing their effect.

Estrogens + Methylprednisolone Acetate, Lidocaine Hydrochloride, Povidine Iodine, Isopropyl Alcohol🟡Moderate

Estrogens may decrease hepatic metabolism of certain corticosteroids, increasing their effect.

Estrogens + Methylprednisolone Sodium Succinate🟡Moderate

Estrogens may decrease the hepatic metabolism of certain corticosteroids, thereby increasing their effect.

Estrogens + Phenytoin🟡Moderate

May increase phenytoin serum levels; monitoring of phenytoin levels recommended.

Estrogens + Phenytoin Sodium🟡Moderate

May increase phenytoin serum levels; monitoring of phenytoin levels recommended.

Estrogens + Prasugrel🟡Moderate

Delay and reduce absorption of prasugrel's active metabolite due to slowed gastric emptying. Consider parenteral antiplatelet agent alternative.

Estrogens + Prasugrel Hydrochloride🟡Moderate

Opioid agonists delay and reduce absorption of prasugrel's active metabolite, presumably due to slowed gastric emptying. Consider parenteral antiplatelet agent in acute coronary syndrome patients.

Estrogens + Prednisolone Sodium Phosphate🟡Moderate

Estrogens decrease hepatic metabolism of certain corticosteroids, increasing their effect.

Estrogens + Prednisone🟡Moderate

Estrogens may decrease hepatic metabolism of corticosteroids, thereby increasing their effect.

Estrogens + Rifampin🟡Moderate

Rifampin decreases estrogen exposure. Advise patients to change to non-hormonal birth control methods during rifampin therapy.

Estrogens + Ropinirole🟡Moderate

Higher doses of estrogens reduce clearance of ropinirole; starting or stopping hormone replacement therapy may require ropinirole dose adjustment.

Estrogens + Sitagliptin And Metformin Hydrochloride🟡Moderate

May produce hyperglycemia and lead to loss of glycemic control. Monitor blood glucose closely during concomitant use.

Estrogens + Somapacitan-Beco🟡Moderate

Oral estrogens may reduce the serum IGF-1 response to SOGROYA, potentially requiring higher SOGROYA dosages.

Estrogens + Somatrogon-Ghla🟡Moderate

Oral estrogens may reduce the serum IGF-1 response to NGENLA. Patients receiving oral estrogen replacement may require higher NGENLA dosages.

Estrogens + Somatropin🟡Moderate

Larger doses of somatropin may be required in women using oral estrogen.

Estrogens + Thalidomide🟡Moderate

Estrogen-containing therapies may increase thromboembolism risk when used concomitantly with thalidomide.

Estrogens + Thyroid🟡Moderate

Estrogens increase serum thyroxine-binding globulin, decreasing free levothyroxine. Patients without functioning thyroid glands on thyroid replacement may need increased thyroid doses.

Estrogens + Thyroid, Porcine🟡Moderate

Increases serum thyroxine-binding globulin (TBg), decreasing free levothyroxine (T4) in patients without functioning thyroid glands. May require increased thyroid dose.

Estrogens + Tizanidine🟡Moderate

Concomitant use not recommended; hypotensive effects may be cumulative.

Estrogens + Tizanidine Hydrochloride🟡Moderate

Concomitant use not recommended; hypotensive effects may be cumulative.

Estrogens + Triamcinolone Acetonide🟡Moderate

Estrogens may decrease hepatic metabolism of corticosteroids, increasing their effect.

Estrogens + Triamcinolone Acetonide Extended-Release Injectable Suspension🟡Moderate

Estrogens may decrease hepatic metabolism of certain corticosteroids, thereby increasing their effect.

Estrogens + Ursodiol🟡Moderate

Increase hepatic cholesterol secretion and may counteract the effectiveness of ursodiol.

Estrogens + Ursosiol🟡Moderate

Increase hepatic cholesterol secretion and encourage cholesterol gallstone formation, potentially counteracting ursodiol effectiveness.

Estrogens + Usodiol🟡Moderate

Increase hepatic cholesterol secretion and encourage cholesterol gallstone formation, potentially counteracting ursodiol effectiveness.

Estrogens + Risedronate Sodium🟢Minor

Risedronate sodium may be used concomitantly with hormone replacement therapy if considered appropriate; study showed no safety concerns.

Data sourced from U.S. FDA drug labeling via openFDA and the NIH National Library of Medicine. For informational purposes only. Always consult your pharmacist or physician.